BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

The Staby® Technology From Delphi Genetics Efficiently Applied to DNA-Vaccine


12/3/2012 10:23:16 AM

CHARLEROI, Belgium--(BUSINESS WIRE)--During the inauguration of its new building, the Belgian Biotech Company Delphi Genetics SA announced that the first antibiotic-free DNA vaccine using the Staby® technology was efficiently tested in vivo. Together with academic and Biotech key-players, Delphi Genetics is participating to the DNAVAC project funded by the Walloon Region (BioWin project). The aim of the project is to develop and produce antibiotic-free DNA vaccines targeting veterinary diseases. As a model, the consortium developed a DNA vaccine against the Aujezsky virus the causative agent of pseudo-rabies. “This virus was selected as it causes systematically an acute and lethal disease in susceptible species, thereby providing an excellent model to test the efficacy of a vaccine candidate. The results of the challenge performed by Dr Anca Reschner are very clear: all vaccinated animals using the Staby® vectors were resistant to the lethal Aujeszky virus.” said Prof. Alain Vanderplasschen from the University of Liège (Immunology-Vaccinology). Cédric Szpirer PhD, Delphi Genetics co-Founder and CEO, explained: “This is the first real DNA vaccine produced using the Staby® technology. Several DNA vectors have been made in the past to generate production of antibodies, but this is the first time that in vivo tests were performed in order to evaluate efficiency against a disease. All production steps of the vaccine were performed efficiently avoiding completely the use of antibiotic-resistance genes as recommended by regulatory authorities (FDA, USDA, EMA). These results validate the use of Staby® outside the field of protein production.”

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->